JUMPCAN(SH:600566) Ge Long Hui A P P·2025-08-22 11:12Core Viewpoint - Jichuan Pharmaceutical (600566.SH) reported a significant decline in both revenue and net profit for the first half of the year, primarily due to changes in market demand and the impact of medical procurement policies [1] Financial Performance - The company achieved operating revenue of 2,748.718 million yuan, a decrease of 31.87% compared to the same period last year [1] - The net profit attributable to shareholders was 724.364 million yuan, down 45.87% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 620.630 million yuan, reflecting a decline of 47.43% compared to the previous year [1] Market Factors - The decline in revenue and net profit was mainly attributed to reduced sales of Pudilan Anti-inflammatory Oral Liquid and Children's Chiqiao Qingre Granules due to changes in terminal market demand [1] - The sales of Rabeprazole Sodium Enteric-coated Capsules were negatively affected by the medical procurement policy, contributing to the overall revenue and profit decline [1]